ClinicalTrials.gg
Not yet recruitingNCT06861374BRIGHT-FITUpdated Mar 6, 2025

Bivalirudin with Prolonged Infusion During PCI Versus Heparin After Fibrinolytic Therapy

An interventional study of Bivalirudin and Unfractionated heparin in ST-segment Elevation Myocardial Infarction (STEMI), sponsored by First Affiliated Hospital Xi'an Jiaotong University. Not yet recruiting. Per ClinicalTrials.gov, last updated 2025-03-06.

Sponsored by First Affiliated Hospital Xi'an Jiaotong University · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
2,400
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 11 studies testing bivalirudin in ST Elevation Myocardial Infarction — 1 open to participants now, 1 under way, none of them phase 3. bivalirudin · ST Elevation Myocardial Infarction.

Planned enrollment
4th of 11
2,400 · median 1,829
Started
2025
the only one that year
No phase
3 of 11
1 open now
Registered
11th of 11
by date
Lead sponsor
2 of 11
First Affiliated Hospital Xi'an Jiaotong University

Among the 11 studies testing bivalirudin in ST Elevation Myocardial Infarction, this one is the 4th largest by planned enrollment, is the only one that started in 2025, is one of 3 with no phase, and was the 11th registered.

ST Elevation Myocardial Infarction

854 studies on the registry are indexed under ST Elevation Myocardial Infarction; 200 are open to participants now.

Browse ST Elevation Myocardial Infarction studies →

Open to participants now

1 of the 11 studies testing bivalirudin in ST Elevation Myocardial Infarction is open now.

About bivalirudin

bivalirudin: first FDA approval 2000 (ANGIOMAX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 ST Elevation Myocardial Infarction studies recruiting now, 76 (62%) set no upper age limit and 20 (16%) stop at 75 or younger; 10 take children under 18; 9 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing bivalirudin in ST Elevation Myocardial Infarction, or all of them as a file.
02

Study summary

This multicenter, randomized controlled trial in China aims to enroll 2,400 patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (PCI) within 24 hours post-fibrinolysis. Participants will be randomly assigned in a 1:1 ratio to receive either bivalirudin or heparin, with follow-up at 30 days and 1 year. The primary endpoint is a composite of all-cause mortality and Bleeding Academic Research Consortium (BARC) type 3 or 5 bleeding at 30 days.

Read the detailed description

Bivalirudin is a direct thrombin inhibitor that exhibits a reversible and transient anticoagulant effect. Randomized trials have shown conflicting results for bivalirudin in reducing the risk of bleeding for ST-segment elevation myocardial infarction (STEMI) patients undergoing primary PCI (PPCI) compared to heparin. Recently, the BRIGHT-4 study, which assigned 6016 STEMI patients to bivalirudin with a prolonged high dose infusion or heparin during PPCI, showed bivalirudin decreased the risk of a composite endpoint of all-cause mortality and bleeding. However, few studies have focused on the safety and efficacy of bivalirudin in PCI post-fibrinolysis. We therefore aim to conduct the Bivalirudin With Prolonged Infusion During PCI Versus Heparin Following Fibrinolytic Therapy (BRIGHT-FIT) trial to examine whether bivalirudin with a high-dose infusion in PCI after fibrinolysis in superior to heparin in reducing mortality and major bleeding.

03

Conditions studied

  • ST-segment Elevation Myocardial Infarction (STEMI)

Keywords

  • STEMI, PCI, fibrinolysis, bivalirudin, heparin, bleeding, mortality
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Any age
  • STEMI patients received fibrinolysis therapy within 12h of symptom onset and are planned to undergo PCI within 24h of symptom onset.
  • Dual antiplatelet drugs must be administrated according to guidelines before PCI (loading doses and maintenance doses of aspirin and clopidogrel or ticagrelor)
  • Patients requiring staged revascularization of non-culprit vessels within 30 days may be enrolled. In such cases the same antithrombotic agents and PCI procedures must be used in the staged procedure consistent with the index procedure PCI, in particular the assigned antithrombin agent heparin vs. bivalirudin);
  • The subject or legal representative has been informed of the nature of the study, understood the provisions of the protocol, was able to ensure adherence, and signed .

Exclusion criteria

Exclusion Criteria:

  • Not suitable for PCI;
  • Mechanical complications (such as ventricular septal rupture, papillary muscle rupture with acute mitral regurgitation, etc.);
  • Cardiogenic shock(Killip IV)
  • Known allergy or to heparin, bivalirudin, aspirin, or both clopidogrel and ticagrelor
  • Patients who underwent PCI in past 30 days
  • Patients in whom the investigators consider inappropriate to participate in this study (eg, have participated in another drug/instrument study or undergoing another drug/instrument study, pregnancy).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
2,400 participants (estimated)

Study arms

  • Experimental
    Bivalirudin

    bivalirudin with a prolonged infusion

    Drug: Bivalirudin

  • Active comparator
    Heparin

    Heparin alone during PCI

    Drug: Unfractionated heparin

Interventions

  • For rescued PCI, do not recommend to include patient who's ACT is more than 350s. If fibrinolysis is successful, monitor ACT and wait till it's lower than 350s before randomization. Monitor ACT before angiography, (1) if ACT\<180, bivalirudin 0.75 mg/kg intravenous bolus loading dose, and immediately followed by intravenous infusion of 1.75 mg/kg/h until 2-4 hours after PCI; (2) if 180s\<ACT\<225s, bivalirudin 0.5mg/kg intravenous bolus loading dose, and immediately followed by intravenous infusion of 1.75 mg/kg/h until 2-4 hours after PCI; (3) if ACT\>225s, bivalirudin intravenous infusion of 1.75 mg/kg/h until 2-4 hours after PCI. (4) ACT be monitored 5 minutes after the first administration, and if ACT is \<225 s, intravenous injection of 0.3 mg/kg of bivalirudin should be administered, and the ACT re-checked to ensure it is \>225 seconds.

  • DrugHeparinStudies of HeparinHeparin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    (1)If ACT\<180s, administer an intravenous bolus of unfractionated heparin at 70 U/kg before coronary angiography, with a maximum total dose of 6000U. (2)If 180\<ACT\<225s, administer an intravenous bolus of unfractionated heparin at 60 U/kg before coronary angiography, with a maximum total dose of 4000U. (3)If ACT\>225s, proceed directly with PCI and maintain 225s\<ACT\<350s.

06

What researchers measure

Primary outcomes

  1. Composite of all-cause death or BARC type 3、5 bleeding

    BARC=Bleeding academic research consortium

    Time frame: 30days

Secondary outcomes

  1. All cause mortality

    Time frame: 30days and 1year

  2. Composite of all-cause death or BARC type 2、3、5 bleeding

    BARC=Bleeding academic research consortium

    Time frame: 30days and 1year

  3. Net adverse clinical events (NACE)

    NACE is defined as a composite of MACCE or BARC type 3、5 bleeding

    Time frame: 30days and 1year

  4. Major adverse cardiac and cerebral events (MACCE)

    MACCE is defined as a composite of all cause death, recurrent myocardial infarction, stroke or ischemic driven target vessel revascuarlization

    Time frame: 30days and 1year

  5. Stent thrombosis

    Definite or probable stent thrombosis according to Academic Research Consortium

    Time frame: 30days

  6. BARC type 3、5 bleeding

    BARC=Bleeding academic research consortium

    Time frame: 30days

  7. BARC type 2、3、5 bleeding

    BARC=Bleeding academic research consortium

    Time frame: 30days

  8. Thrombocytopenia

    defined as platelet counts less than 150\*10\^9/L after treatment

    Time frame: 30days

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2025; primary completion for Mar 2028, 34 months later.

Of 134 non-industry interventional studies with no phase under ST Elevation Myocardial Infarction, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 64. This study's planned 34 months is below that.

Counting every sponsor, half of 143 studies reached it within 38 months; a quarter within 19 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2025
First posted
Mar 6, 2025
StartEst.
May 2025
Primary completionEst.
Mar 2028
CompletionEst.
Mar 2029
Last update
Mar 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06861374
Responsible party
Sponsor
First posted
Mar 6, 2025
Start date
May 2025 (estimated)
Primary completion
Mar 2028 (estimated)
Completion
Mar 2029 (estimated)
Last update
Mar 6, 2025

Study contacts

Tao Chen, MD
Contact
chentao0331@xjtu.edu.cn
(86)13891995622
Chenbo Xu, MD
Contact
xuchenbox@qq.com
(86)13468763406

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bivalirudin

Start the discussion